Abstract
Objectives
The intravenous injection of bisphosphonates, currently used as treatment for osteoporosis, bone Paget’s disease, multiple myeloma, or bone metastases, can cause jaw bone necrosis especially in consequence of trauma. The present research aimed to clarify the mechanisms underlying bone necrosis, exploring involvement of the oral mucosa “in vivo.”
Patients and methods
Specimens of oral mucosa were removed from bisphosphonate-treated patients with or without jaw bone necrosis. In mucosa specimens, expression was evaluated of: cytokines involved in the inflammatory process, factors involved in osteoclast activity, i.e., receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin, a factor involved in cell proliferation, namely hydroxymethylglutaryl coenzyme A reductase, and a factor involved in angiogenesis, namely vascular endothelial growth factor (VEGF).
Results
Interleukin (IL)-6 and the RANK/osteoprotegerin ratio were significantly elevated in mucosa from patients with versus without jaw necrosis, whereas hydroxymethylglutaryl coenzyme A reductase and VEGF were significantly decreased.
Conclusions
Our results suggest that mucosa, stimulated by bisphosphonate released from the bone, can contribute to the development of jaw necrosis, reducing VEGF, and producing IL-6 in consequence of hydroxymethylglutaryl coenzyme A reductase reduction. In turn, IL-6 stimulates osteoclast activity, as shown by the increased RANKL/osteoprotegerin ratio.
Clinical relevance
The results of this study suggest the importance of evaluating during bisphosphonate treatment the production of IL-6, RANKL, osteoprotegerin, and VEGF, in order to monitor the jaw osteonecrosis onset. To avoid repeated mucosa excisions, the determination of these factors could be carried out in crevicular fluid.
Similar content being viewed by others
References
Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103:232–240
Mehrotra B (2009) Bisphosphonates—role in cancer therapies. J Oral Maxillofac Surg 67:19–26
Dunford JE, Kwaasi AA, Rogers MJ et al (2008) Structure–activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51:2187–2195
Marcus R, Feldman D, Nelson D et al (2008) Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson D, Rosen C (eds) Osteoporosis, 3rd edn. Elsevier, Burlington, pp 1725–1742
Frei M, Bornstein MM, Schaller B et al (2010) Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. J Oral Maxillofac Surg 68:863–867
Treister NS, Sook-Bin W (2009) Bisphosphonate-associated osteonecrosis of the jaws. In: Rosen CJ, Compston JE, Lian JB (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. Wiley, Hoboken, pp 505–509
Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients, and by “in vitro” research. Clin Cancer Res 9:2893–2897
Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544
Hansen T, Kunkel M, Weber A et al (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160
Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689
Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44:4–10
Ohe JY, Kwon YD, Lee HW (2012) Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig 16:1153–1159
Koch FP, Merkel C, Ziebart T et al (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 16:79–86
Mozzati M, Gallesio G, Arata V et al (2012) Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 48:469–474
Mozzati M, Martinasso G, Cocero N et al (2011) Influence of superpulsed laser therapy on healing processes following tooth extraction. Photomed Laser Surg 29:565–571
Bianchi SD, Scoletta M, Cassione FB et al (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:249–258
Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474
Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432
La Verde N, Bareggi C, Garassino M et al (2008) Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer 16:1311–1315
Ruggiero S, Gralow J, Marx RE et al (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7–14
Vandone AM, Donadio M, Mozzati M et al (2011) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200
Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253
Shannon J, Shannon J, Modelevsky S et al (2011) Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 340:c246. doi:10.1111/j.1532-5415.2011.03713.x
Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Oteoporos Int 9:S66–S80
Santini D, Vincenzi B, Caraglia M et al (2007) A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol 18:201–202
Rufo A, Del Fattore A, Capulli M et al (2011) Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 26:1891–1903. doi:10.1002/jbmr.410
Jimi E, Furuta H, Matsuo K et al (2010) The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 17:462–468. doi:10.1111/j.1601-0825.2010.01781.x
Hewitt RE, Lissina A, Green AE et al (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111
Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761
Kraus D, Deschner J, Jäger A et al (2012) Human β-defensins differently affect proliferation, differentiation, and mineralization of osteoblast-like MG63 cells. J Cell Physiol 227:994–1003. doi:10.1002/jcp.22808
Krishnan V, Shuman LA, Sosnoski DM et al (2011) Dynamic interaction between breast cancer cells and osteoblastic tissue: comparison of two- and three-dimensional cultures. J Cell Physiol 226:2150–2158
Landesberg R, Woo V, Cremers S et al (2011) Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 1218:62–79. doi:10.1111/j.1749-6632.2010.05835.x
Rustemeyer J, Bremerich A (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 14:59–64
Acknowledgments
The work was supported by grants from Regione Piemonte and University of Turin, Italy.
Conflicts of interest
The authors declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mozzati, M., Martinasso, G., Maggiora, M. et al. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. Clin Oral Invest 17, 1259–1266 (2013). https://doi.org/10.1007/s00784-012-0800-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-012-0800-7